Review Article

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer

Table 1

Genomic and proteomic features of basal-like breast cancer (data from TCGA [7]).

Pathways and analysisAberrations

TP53 pathwayTP53 mut (84%); gain of MDM2 (14%)
PIK3CA/PTEN pathwayPIK3CA mut (7%); PTEN mut/loss (35%); INPP4B loss (30%)
RB1 pathwayRB1 mut/loss (20%); cyclin E1 amp (9%); high expression of CDKN2A; low expression of RB1
Copy numberMost aneuploid; high genomic instability; 1q, 10p gain; 8p, 5q loss; MYC focal gain (40%)
Proteomic analysis by reverse phase protein arrayHigh expression of DNA repair proteins, PTEN and INPP4B loss signature (pAKT)